Skip to main content

Table 1 Clinical inputs considered in the model

From: Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study

  Value of the parameter
  Ranolazine (%) SoC (%)
Transition probabilities
 Adherence to treatment with ranolazine [23] 0.720  
 Angina frequency [22]
  Minimum 0.040 0.000
  Mild 0.605 0.071
  Moderate 0.208 0.689
  Severe 0.137 0.241
 Hospitalization [25]
  With minimum angina frequency 0.200 0.200
  With mild angina frequency 0.200 0.200
  With moderate angina frequency 0.270 0.270
  With severe angina frequency 0.300 0.300
 Revascularization [26]
  Revascularization 0.500 0.500
  Revascularization with CABG 0.280 0.280
  Revascularization with PTCA 0.720 0.720
 Utility values [27]
  No hospitalization, minimum angina frequency 0.810 0.840
  No hospitalization, mild angina frequency 0.750 0.750
  No hospitalization, moderate angina frequency 0.600 0.600
  No hospitalization, severe angina frequency 0.390 0.390
  Hospitalization without revascularization, minimum angina frequency 0.800 0.800
  Hospitalization without revascularization, mild angina frequency 0.740 0.740
  Hospitalization without revascularization, moderate angina frequency 0.590 0.590
  Hospitalization without revascularization, severe angina frequency 0.380 0.380
  Revascularization, minimum angina frequency 0.750 0.750
  Revascularization, mild angina frequency 0.690 0.690
  Revascularization, moderate angina frequency 0.540 0.540
  Revascularization, severe angina frequency 0.330 0.330
  1. CABG: coronary artery bypass graft, PCI/STENT: percutaneous transluminal angioplasty & stenting, SoC: standard of care